All participants first took semaglutide for 20 weeks and lost 10.6% of their weight on average. Then they were split: some stayed on semaglutide 2.4 mg, others were switched without knowing it to placebo. Over the next 48 weeks, those who stayed on lost another 7.9%, while those on placebo regained 6.9%. It was published in JAMA in 2021.1
How the trial was run
The trial ran at 73 sites in 10 countries from June 2018 to March 2020. It enrolled adults with a body mass index of 30 or more, or 27 or more with a weight-related condition, and without diabetes.1
- Run-in. 902 people took semaglutide for 20 weeks: 16 weeks of rising doses and 4 weeks at 2.4 mg.
- Split. The 803 who reached 2.4 mg, 89.0% of them, were assigned two to one to continue semaglutide, 535 people, or switch to placebo, 268 people.
- Follow-up. Both groups had a lifestyle program for the remaining 48 weeks.
At the split, the participants averaged 46 years of age and 107.2 kg, and 79% were women. Almost all finished: 98.0% completed the trial and 92.3% completed treatment.1
What it found
- From week 20 to week 68, weight changed by −7.9% on semaglutide and +6.9% on placebo, a gap of 14.8 percentage points.
- Waist size, systolic blood pressure and physical functioning also improved more with continued semaglutide.
- Stomach and gut events were reported by 49.1% on semaglutide and 26.1% on placebo. Similar shares stopped because of adverse events, 2.4% and 2.2%.
Rubino et al., 2021.1
What it means
STEP 4 is the clearest evidence that semaglutide works only while it is taken. Those switched to placebo regained most of what they had lost in the run-in, within about a year. The authors' conclusion was that maintaining treatment kept the weight loss going, while stopping led to regain.1 That is why the Wegovy label describes the goal as reducing excess body weight and maintaining the reduction long term.2
Tirzepatide showed the same pattern in its own withdrawal trial, SURMOUNT-4, which the Zepbound label includes as its fourth weight study.3 There, 670 people lost 20.9% over a 36-week lead-in. From week 36 to week 88, those who stayed on tirzepatide lost another 5.5%, while those switched to placebo regained 14.0%. At week 88, 89.5% of those on tirzepatide had kept at least 80% of their earlier loss, against 16.6% on placebo.4 Two drugs, two trials, the same lesson. Our page on the Zepbound plateau covers what happens when weight stops falling but the drug continues.
In practice
For people who have to stop, often because coverage ends, the two trials set expectations. Neither group returned all the way to its starting weight within a year: in SURMOUNT-4, the placebo group still ended 9.9% below where it began at week 0, against 25.3% for those who stayed on tirzepatide.4 But most of the benefit faded, and the trials do not show what happens after longer. Our page on GLP-1 costs without insurance lists the self-pay options that can bridge a gap in coverage.
Limits
Everyone in STEP 4 had already reached the full dose and tolerated it, so the trial describes people who did well in the first 20 weeks. The label makes the same point about its withdrawal study: those who did not reach 2.4 mg could not continue, so the results may not reflect people just starting.2 Stopping was also abrupt; the trial does not show what a gradual taper or a lower maintenance dose would do. Several authors report financial ties to Novo Nordisk, the maker of semaglutide.1
Sources
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-1425. NCT03548987. doi:10.1001/jama.2021.3224
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 14. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026, section 14; ClinicalTrials.gov record NCT04660643 (SURMOUNT-4). accessdata.fda.gov
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
Related analyses
Zepbound plateau: when weight loss slows, why, and what the trials show
Wegovy weight loss chart: the trial results week by week, in your own weight
Switching from Wegovy to Zepbound: the starting dose, the timing, and what the evidence covers
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Log your weight weekly, on and off treatment, and see the trend for yourself.
Open Dose Insider